




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61F 2/04	A1	(11) International Publication Number: WO 93/16659 (43) International Publication Date: 2 September 1993 (02.09.93)
(21) International Application Number: PCT/US93/01797 (22) International Filing Date: 1 March 1993 (01.03.93) (30) Priority data: 843,669 28 February 1992 (28.02.92) US (71) Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH[US/US]; 200 First Street Southwest, Rochester, MN 55905 (US). (72) Inventor: BARRETT, David, Michael ; 4720 - 55th Avenue Southwest, Rochester, MN 55902 (US). (74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Welter & Schmidt, 3100 Norwest Center, 90 South Seventh Street, Minneapolis, MN 55402 (US).		(81) Designated States: European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>

(54) Title: ARTIFICIAL BLADDER**(57) Abstract**

An apparatus for use as an artificial bladder (10) for implantation into a patient. The apparatus is comprised of a bladder (11) having a rigid outer shell (24) and a flexible inner shell (25) that are connected at a bladder neck (26) thereby creating an open space (27) between the outer shell and inner shell that contains a biocompatible fluid, a storage unit (12) for storing the biocompatible fluid at a pressure lower than the pressure inside the bladder, a pumping unit (13) for creating a positive pressure to pump the biocompatible fluid from the storage unit to the open space in the bladder, a ureter replacement unit for allowing urine to move from the kidneys to the inner shell of the bladder, a valve unit (14) for allowing the urine to exit the bladder, a ureter replacement unit (15) for allowing the urine to exit the body from the valve unit and tubing units (16) for allowing the biocompatible fluid to move between the bladder, storage unit and pumping unit.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

ARTIFICIAL BLADDER

Field of Invention

This invention relates to an implantable artificial
5 bladder for the collection of, the storage of, and
discharge of biological fluids, more particularly urine,
in a patient whose natural bladder failed or has been
removed.

10 Background of Invention

The estimated incidence of bladder carcinoma in the
United States in 1990 is 49,000. Of these patients,
3,000 will have a cystectomy performed, and many more
cystectomies and urinary diversions will be done for
15 disabling functional disorders of the bladder.

At the present time, these patients are provided
with conduits, continent pouches or ureterosigmoidostomy.
Although these intestinal urinary diversions are markedly
better than bilateral ureterostomies, the long list of
20 physical and psychological complications associated with
their use has spurred investigation into a total
alloplastic replacement of the lower urinary tract.
Several set-backs, however, have arisen with the present
design of the replacement devices. The three main
25 problem areas that still need to be overcome are renal
failure from hydronephrosis, infection from urinary
stasis and external connections and encrustation of the
luminal surface.

Most artificial bladder replacements have relied on
30 ureteric pressure to expand a flexible bladder.
Unfortunately, when these bladders are placed intra-
abdominally, a fibrous capsule has developed around the
prosthesis restricting the filling of the bladder. This
restriction can cause a retention of urine by the kidneys
35 and the development of hydronephrosis.

In addition, in most prosthesis, gravity has been
the basis of bladder emptying. Although this has been
effective on bench testing, most models have been found
to have large residual volumes of urine after

implementation. A fibrous capsule can also cause retention of urine because it inhibits complete collapse of the bladder. The presence of this residual urine increases the risk of encrustation and can lead to
5 infection and stone formation. Therefore, there arises the need for an artificial bladder that overcomes hydronephrosis and reduces the risk of infection and encrustation.

10 Summary of Invention

The present invention is for an artificial bladder that reduces the risk of hydronephrosis by negative pressure drainage of the kidneys. The invention also reduces the risk of infection and encrustation by active
15 voiding of the bladder system to insure that no residual urine remains in the bladder after emptying.

The invention incorporates a bladder with a hard outer shell and a collapsible inner shell. The outer and inner shell are connected at a bladder neck leaving an
20 open space between the outer shell and the inner shell that is filled with a biocompatible fluid. The hard outer shell of the invention prevents any interference from the surrounding tissues to prevent them from restricting the filling or emptying of the bladder.

25 The bladder is connected in series with a reservoir that is arranged and configured to create a negative pressure gradient between the reservoir in the bladder and a pumping means to enable the biocompatible fluid to flow between the bladder, reservoir and pump. Ureter
30 tubes are connected to the kidneys and to the bladder neck so that urine can flow from the kidneys to the bladder inner shell. The negative pressure gradient between the reservoir and the bladder causes the biocompatible fluid to flow from the open space in the
35 bladder to the reservoir, which in turn causes urine to be drawn from the kidneys into the bladder inner shell.

This negative pressure drainage of the kidneys prevents backflow of urine from the bladder to the kidneys, therefore, preventing renal failure from hydronephrosis.

When the bladder is full, the patient activates the
5 pump causing biocompatible fluid to flow from the reservoir, through the pump and into the open space in the bladder. As the biocompatible fluid is forced into the open space from the pump the bladder inner shell collapses forcing the urine through a valve and out of
10 the body. This active voiding of urine from the bladder assures that no urine remains in the bladder, therefore, reducing the risk of an infection and encrustation.

Brief Description of the Drawings

15 FIG. 1 is a front elevational view of the preferred embodiment of the invention;

FIG. 2 is a side elevational view of the preferred embodiment of the invention with portions of the reservoir cut away;

20 FIG. 3 is an elevational view of the preferred embodiment of the urethral valve in its closed position;

FIG. 4 is an elevational view of the preferred embodiment of the urethral valve as positioned when the bladder is full;

25 FIG. 5 is an elevational view of the preferred embodiment of the urethral valve in its open position;

FIG. 6 is a schematic illustration of the reservoir as shown when the reservoir is empty.

30 Detailed Description of the Preferred Embodiment

Referring to the drawings wherein like numerals designate like parts, the preferred embodiment of the invention is an artificial bladder 10 generally shown in FIG. 1 for implementation into a patient. The artificial
35 bladder 10 is comprised of a bladder generally identified as 11, a reservoir generally identified as 12, a pump 13,

a urethral valve 14, a urethra tube 15, ureter tubes 16, a first tubing member 17, a second tubing member 18, a third tubing member 19 and a fourth tubing member 20.

The bladder 11 is comprised of a 300-ml hard outer
5 shell 24 made of rigid polysulphone and a 230-ml flexible inner shell 25 made of silicone. The outer shell 24 and inner shell 25 are connected at the bladder neck 26 creating an open space 27 between the outer shell 24 and inner shell 25. The inner shell 25 is flexible and
10 expands as urine enters the bladder 11. The open space 27 contains saline or some other suitable biocompatible fluid and is separated from the urine stream by the attachment of the inner shell 25 at the bladder neck 26.

In the preferred embodiment, the ureter tubes 16 are
15 made of 8-f silicone tubing reinforced with a nylon spiral to prevent kinking. The proximate end of ureter tube 16 contains a 4.5-f silicone pigtail 21 for insertion into the renal pelvis, and a 0.5-cm. dacron cuff 22 that is used to facilitate anastomosis with the
20 uretic stump. The placement of the pigtail 21 in the renal pelvis overcomes the problem of papilloma formation by reducing irritation and increasing the distance of the connection of the ureter tube 16 from the site of anastomosis.

25 At the distal end of the ureter tube 16 is a silicone latex rubber duckbill antireflux valve 23. This antireflux valve 23 allows urine to flow through the ureter tube 16 to the inner shell 25 of the bladder 11 during the filling of the bladder 11, but prevents the
30 flow of urine from the inner shell 25 to the ureter tube 16 during the emptying of the bladder 11.

The reservoir 12, best shown in FIG. 2, is comprised of a polysulphone rigid base 28, generally shaped like a truncated cone, and a flexible silicone dome 29, which
35 are compressed together by two stainless steel rings 30 to form a fluid tight chamber. An 11-cm. stainless steel

spring 31 is located inside the reservoir 12 with one end attached to the rigid base 28 and the other end attached to the flexible dome 29. This reservoir 12 arrangement is used to create a negative pressure gradient as

5 compared to the secretory pressure of the kidney which is believed to be between 2 and 10 cm of H₂O.

The pump 13 is preferably of a manual operation design and is placed on the inside of the patient near the skin in a location that is easily accessible by the
10 patient. One such location could be the scrotum. The pump 13 used in this preferred embodiment is made of silicone and is unidirectional having a 2-ml volume. Those skilled in the art would recognize that electrical or electro- mechanical pumps could also be used.

15 One end of an 8-f first tubing member 17 is attached to an aperture in the outer shell 24 of the bladder 11 and the opposite end of the first tubing member 17 is attached to an aperture in the reservoir rigid base 28, thereby enabling saline to travel from the bladder 11 to
20 the reservoir 12. The negative pressure gradient between the reservoir 12 and bladder 11 causes saline to flow from the bladder 11 to the reservoir 12. The first tubing member 17, therefore, also contains a polysulphone orifice 32 to regulate the rate of fluid moving from the
25 bladder 11 to the reservoir 12. Four parallel ceramic filters 33 are also contained in the first tubing member 17 and are located between the bladder 11 and the orifice 32 to remove any particulate matter that might obstruct the orifice 32.

30 One end of a 8-f silicone second tubing member 18 is attached to an aperture in the rigid base 28 of the reservoir 12 and the other end is attached to the pump 13 to allow saline to flow from the reservoir 12 to the pump 13. One end of an 8-f silicone third tubing member 19 is
35 attached to the pump 13 and the other end is attached to an aperture in the outer shell 24 of the bladder 11. The

third tubing member 19 also contains an antireflux valve 43 at the attachment to the bladder 11 to allow saline to flow from the pump 13 to the bladder 11, but preventing saline from flowing from the bladder 11 to the pump 13.

5 The preferred embodiment of the urethral valve 14, best shown in FIGS. 3-5, is a machined polysulphone valve that is divided into a first chamber 34 and a second chamber 35. The first chamber 34 is connected both to the urethra tube 15 and to the bladder neck 26 and thus
10 acts as the urine conduit. A stainless steel poppit 36 with a sharp rim 37 around its edge is located in the first chamber 34 on one end of a central rod 39. The sharp rim 37 abuts a silicone seat 38 to create a watertight seal that obstructs urine flow when the
15 urethral valve 14 is closed. The central rod 39 extends through both the first chamber 34 and second chamber 35 and is supported by flexible silicone diaphragms 40 which enable the central rod 39 to move back and forth in an axial direction. A valve spring 41 and screw cap 42 are
20 located on the end of the central rod 39 opposite to the poppit 36 to insure that the urethral valve 14 is closed when in the resting position. The screw cap 42 can be adjusted to change the amount of compression in the valve spring 41 to change the opening or leak pressure of the
25 urethral valve 14.

The second chamber 35 is connected to the reservoir 12 and the pump 13 by an 8-f silicone fourth tubing member 20 that has one end attached to the second chamber 35, a second end attached to the first tubing member 17
30 and a third end attached to the third tubing member 19. The second chamber 35 is thereby placed in fluid connection with the reservoir 12 and the pump 13.

The preferred embodiment of the urethral tube 15 is an 18-f silicone tube with a dacron cuff 44 generally
35 located at its proximal end for attachment to the urethral stump. In the preferred embodiment, the urethra

tube 15 extends beyond the sphincter to eliminate the problems with urine leaks at the urethral anastomosis that exist in shorter ureter tube 15 designs.

During bladder filling, the negative pressure in the reservoir 12 causes saline to be drawn from the open space 27 in the bladder 11 through the first tubing member 17 and into the reservoir 12. This removal of saline creates a negative pressure in the inner shell 25 of the bladder 11 causing urine to be drawn from the kidneys, through the ureter tube 16 and into the inner shell 25 of the bladder 11. This negative pressure drainage of the kidneys eliminates the problem of hydronephrosis that can be present with existing designs.

The negative pressure in the reservoir 12 also causes the diaphragm 40 located in the second chamber 35 of the urethral valve 14 to be drawn axially toward the poppit 36 helping to seal the first chamber 34, FIG. 3. As the reservoir 12 continues to fill with saline, the pressure in the reservoir will increase, reducing the negative pressure gradient between the reservoir 12 and the bladder 11. When the inner shell 25 of the bladder 11 is full, the pressure from the urine on the diaphragm 40 in the first chamber 34 will be great enough to cause the poppit 36 to open slightly allowing a small amount of urine to leak through the first chamber 34, FIG. 4. This leakage acts as a signal to the patient that the bladder 11 is full and needs to be emptied.

The patient then activates the pump 13 to empty the bladder 11. As the pump 13 is activated, the pressure of the saline in the second chamber 35 is increased forcing the diaphragm 40 in the second chamber 35 of the urethral valve 14 to move toward the valve spring 41, forcing the central rod 39 to move toward the valve spring 41 and opening the first chamber 34, FIG. 5. The activated pump 13 also draws saline from the reservoir 12 and forces it into the open space 27 increasing the pressure in the

bladder 11 and causing the inner shell 25 to collapse. The collapsing of the inner shell 25 assures that the bladder 11 is completely emptied. However, this increased pressure in the bladder 11 requires the use of
5 the antireflux valves 23 on the ureter tubes 16 to prevent urine from backing up into the kidneys.

In addition, as the pump 13 draws saline from the reservoir 12, the pressure in the reservoir 12 is decreased causing the silicone dome 29 to collapse and
10 the spring 31 to compress, FIG. 6. By the time the patient discontinues the use of the pump 13, the pressure in the reservoir 12 is again lower than the pressure of the bladder 11, causing the saline to be drawn from the bladder 11 to the reservoir 12 and urine to be drawn from
15 the kidneys to the bladder 11. As saline continues to enter the reservoir 12, the pressure in the reservoir 12 will increase, allowing the spring 31 to expand moving the silicone dome 29 outward and thereby increasing the volume of the reservoir 12. The changing volume of the
20 reservoir 12 creates a smooth pressure transition as the reservoir 12 fills with saline and the pressure of the reservoir 12 increases.

Although characteristics and advantages together with details for structure, materials, function and
25 process steps have been described in reference to a preferred embodiment herein, it is understood that the disclosure is illustrative. To that degree, various changes made, especially to the matters of shape, size and arrangement, to the full extent extended by the
30 general meaning of the terms in which the appended claims are expressed, are within the principals of the present invention.

WHAT IS CLAIMED IS

1. An artificial bladder comprising:

- 5 (a) a bladder having a rigid outer shell and an inner flexible shell that are connected at a bladder neck thereby creating an open space between said outer shell and said inner flexible shell;
- 10 (b) a reservoir having a rigid base and a flexible dome, and a means for securing said flexible dome to said rigid base thereby creating a fluid tight inner opening with a variable volume;
- 15 (c) a spring-type member located within said inner opening of said reservoir with first and second ends wherein said first end is connected to said rigid base and said second end is connected to said flexible dome;
- 20 (d) a pumping means for pumping biocompatible fluid from said reservoir to said open space in said bladder;
- 25 (e) a urethra tube arranged and configured to allow urine to exit the body;
- 30 (f) a urethral valve having first and second chambers attached to said neck of said bladder and to said urethra tube, said first chamber arranged and configured to allow urine to flow from said bladder to said urethra tube and said second chamber arranged and configured to be in fluid connection with said pump and said reservoir, and a valve arranged and configured to open and close said first chamber;
- (g) ureter tubes having first and second ends wherein said first end is arranged and configured to allow urine to flow from the kidneys into said ureter tube and having an antireflux valve that is

arranged and configured to allow the flow of urine from the kidneys to the bladder, but preventing the flow of urine from the bladder to the kidneys;

- 5 (h) a first tubing member with first and second ends, wherein said first end is connected to said reservoir and said second end is connected to said bladder whereby said biocompatible fluid can flow from said open space in said bladder to said reservoir;
- 10 (i) a second tubing member with first and second ends, wherein said first end is connected to said reservoir and said second end is connected to said pump whereby said biocompatible fluid can flow from said reservoir to said pump;
- 15 (j) a third tubing member with first and second ends, wherein said first end is connected to said pump and said second end is connected to said bladder by a antireflux valve, whereby said biocompatible fluid can flow from said pump to said open space in said bladder, but said biocompatible fluid cannot flow from said open space in said bladder to said pump; and
- 20 (k) a fourth tubing member with a first end connected to said urethral valve second chamber, a second end connected to said first tubing member and a third end connected to said third tubing member, whereby said second chamber of said urethral valve is in fluid connection with said reservoir and said pump.
- 25
- 30

2. An artificial bladder comprising:

- (a) a bladder having a rigid outer shell and an inner flexible shell that are connected at a bladder

- neck thereby creating an open space between said outer shell and said inner flexible shell that contains a biocompatible fluid;
- 5 (b) a means for storing said biocompatible fluid at a pressure lower than the pressure inside said bladder;
- (c) a means for allowing said biocompatible fluid to flow from said bladder open space to said storage means;
- 10 (d) a pumping means for creating a positive pressure to pump said biocompatible fluid from said storage means to said open space in said bladder;
- (e) a means for allowing said biocompatible fluid to move from said storage means to said pumping means;
- 15 (f) a means for allowing said biocompatible fluid to move from said pumping means to said open space in said bladder;
- (g) a means for allowing urine to move from the kidneys to said bladder;
- 20 (h) a means for preventing urine from moving from said bladder to the kidneys;
- (i) a valve means for allowing urine to exit said bladder; and
- 25 (j) a means for allowing urine to exit the body from said valve means.
3. An artificial bladder according to claim 2 wherein said means for allowing urine to flow from the kidneys to said bladder is silicone tubing reenforced with a nylon spiral to prevent kinking.
- 30

4. An artificial bladder according to claim 2 wherein said means for preventing urine from flowing from the bladder to the kidneys is an antireflux valve.
- 5 5. An artificial bladder according to claim 2 wherein said means for allowing the movement of biocompatible fluid from said bladder to said storage means comprises a silicone tube with an orifice for regulating the flow rate of the biocompatible fluid.
- 10 6. An artificial bladder according to claim 2 wherein said pumping means is a manually operated silicone pump generally located inside the patient near the skin.
- 15 7. An artificial bladder according to claim 2 wherein said valve means for allowing urine to exit the bladder is comprised of a valve with first and second chambers, said first chamber connecting said bladder to said means for allowing the urine to exit the body and said
20 second chamber arranged and configured to be in fluid contact with said storage means and said pump, and a spring loaded poppit that seals off said first chamber, but opens said first chamber when the pressure of said biocompatible fluid is increased during the operation
25 of the pumping means.
8. An artificial bladder according to claim 2 wherein said means for storing said biocompatible fluid is a reservoir having a rigid base and a flexible dome and a
30 means for securing said flexible dome to said rigid base thereby creating a fluid type inner opening with a variable volume, and a spring type member located within said inner opening with first and second ends

wherein said first end is connected to said rigid base and said second end is connected to said flexible dome.

- 9.. A reservoir according to claim 8 wherein said means for
5 securing said flexible dome to said rigid base is a pair of steel rings that compress the flexible dome to the rigid base.
10. An artificial bladder according to claim 2 wherein said
10 means for allowing said biocompatible fluid to move from said storage means to said pumping means is a silicone tube.
11. An artificial bladder according to claim 2 wherein said
15 means for allowing said biocompatible fluid to move from said pumping means to said open space is a silicone tube with an antireflux valve to allow said biocompatible fluid to flow from said pumping means to said open space, but preventing said biocompatible
20 fluid from moving from said open space to said pumping means.
12. An artificial bladder according to claim 2 wherein said
25 means for allowing urine to exit the body is a silicone tube that is attached to said valve means.





FIG. 5




FIG. 4




FIG. 3





FIG. 6



INTERNATIONAL SEARCH REPORT

PCT/US93/01797

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) :A61F 2/04

US CL :623/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 623/12 623/11, 600/29-31

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A, 5,019,102 (Hoene) 28 May 1991 See Abstract and figures.	1-12
A	US,A, 4,976,735 (Griffith et al.) 11 December 1990 See the entire reference.	1-12
A	US,A, 4,961,747 (Wascher et al.) 09 October 1990 See the entire reference.	1-12
A	US,A, 5,041,077 (Kulick) 20 August 1991 See Abstract & figures.	1-12
Y	US,A, 5,012,822 (Schwarz) 07 May 1991 See the entire reference.	1-12

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

A	Special categories of cited documents: document defining the general state of the art which is not considered to be part of particular relevance	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
E	earlier document published on or after the international filing date	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combinations being obvious to a person skilled in the art
O	document referring to an oral disclosure, use, exhibition or other means		
P	document published prior to the international filing date but later than the priority date claimed	*Z*	document member of the same patent family

Date of the actual completion of the international search

18 APRIL 1993

Date of mailing of the international search report

09 JUN 1993

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. NOT APPLICABLE

 Authorized officer *my mark*
 ELIZABETH BURKE

Telephone No. (703) 308-2996

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US,A, 4,969,474 (Schwarz) 13 November 1990 See the entire reference.	1-12
A	US,A, 4,222,377 (Burton) 16 September 1980 See Abstract & figures	1-12
A	US,A, 4,167,952 (Reinicke) 18 September 1979 See Abstract and figures.	1-12